Patients with anti-MDA5-positive DM (anti-MDA5+ DM) are characterized by four primary clinical features: the presence of anti-MDA5 antibodies, skin ulcers, muscle weakness or absence of myositis, and interstitial lung disease (ILD), particularly rapidly progressive ILD (RP-ILD) (3, 4). This evidence concerns the gene IFIH1 and myositis disease.